静脉注射利多卡因治疗纤维肌痛综合征的疗效及不良反应
Efficacy and adverse effects of intravenous lignocaine therapy in fibromyalgia syndrome.
作者信息
Raphael J H, Southall J L, Treharne G J, Kitas G D
机构信息
Department of Pain Management, Dudley Group of Hospitals NHS Trust, West Midlands, UK.
出版信息
BMC Musculoskelet Disord. 2002 Sep 8;3:21. doi: 10.1186/1471-2474-3-21.
BACKGROUND
To investigate the effects of intravenous lignocaine infusions (IV lignocaine) in fibromyalgia.
METHODS
Prospective study of the adverse effects of IV lignocaine in 106 patients with fibromyalgia; retrospective questionnaire study of the efficacy of IV lignocaine in 50 patients with fibromyalgia.
RESULTS
Prospective study: Two major (pulmonary oedema and supraventricular tachycardia) and 42 minor side-effects were reported. None had long-term sequelae. The commonest was hypotension (17 cases). Retrospective study: Pain and a range of psychosocial measures (on single 11-point scales) improved significantly after treatment. There was no effect of the treatment on work status. The average duration of pain relief after the 6-day course of treatment was 11.5 +/- 6.5 weeks.
CONCLUSIONS
Intravenous lignocaine appears to be both safe and of benefit in improving pain and quality of life for patients with fibromyalgia. This needs to be confirmed in prospective randomised controlled trials.
背景
研究静脉注射利多卡因（IV利多卡因）对纤维肌痛的影响。
方法
对106例纤维肌痛患者进行IV利多卡因不良反应的前瞻性研究；对50例纤维肌痛患者进行IV利多卡因疗效的回顾性问卷调查研究。
结果
前瞻性研究：报告了2例严重不良反应（肺水肿和室上性心动过速）和42例轻微不良反应。均无长期后遗症。最常见的是低血压（17例）。回顾性研究：治疗后疼痛及一系列心理社会指标（采用单一的11分制量表）有显著改善。治疗对工作状态无影响。6天疗程治疗后疼痛缓解的平均持续时间为11.5±6.5周。
结论
静脉注射利多卡因似乎对改善纤维肌痛患者的疼痛和生活质量既安全又有益。这需要在前瞻性随机对照试验中得到证实。
Zotero 插件